Nautilus Biotechnology Yönetim

Yönetim kriter kontrolleri 3/4

Nautilus Biotechnology CEO'su Sujal Patel, Jun2021 tarihinde atandı, in görev süresi 3.42 yıldır. şirketin hisselerinin 13.67% doğrudan sahiptir ve bu hisselerin değeri $ 45.30M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 3.4 yıldır.

Anahtar bilgiler

Sujal Patel

İcra Kurulu Başkanı

US$1.9m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.4yrs
CEO sahipliği	13.7%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	3.4yrs

Son yönetim güncellemeleri

Recent updates

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

Jul 27

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 16

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

Oct 22

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

May 25

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Feb 17

CEO Tazminat Analizi

Sujal Patel'un ücretlendirmesi Nautilus Biotechnology'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$70m
Jun 30 2024	n/a	n/a	-US$70m
Mar 31 2024	n/a	n/a	-US$67m
Dec 31 2023	US$2m	n/a	-US$64m
Sep 30 2023	n/a	n/a	-US$60m
Jun 30 2023	n/a	n/a	-US$58m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	US$2m	US$500k	-US$58m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$62m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$7m	US$437k	-US$50m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$251k	US$200k	-US$16m

Tazminat ve Piyasa: Sujal 'ın toplam tazminatı ($USD 1.89M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.40M ).

Tazminat ve Kazançlar: Sujal şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sujal Patel (49 yo)

3.4yrs

Görev süresi

US$1,892,862

Tazminat

Mr. Sujal M. Patel serves as the Sage at Defy Partners since joining the firm in April 2019. He is Co-Founder of Nautilus Biotechnology, Inc. and has been its Chief Executive Officer, President, Secretary...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sujal Patel	Co-Founder	3.4yrs	US$1.89m	13.67% $ 45.3m
Parag Mallick	Co-Founder	3.4yrs	US$1.02m	16.47% $ 54.6m
Anna Mowry	CFO & Treasurer	3.4yrs	US$781.52k	0.048% $ 159.7k
Matthew Murphy	General Counsel	3.4yrs	US$2.87m	Veri yok
Chris Blessington	Vice President of Corporate Marketing & Communications	3.8yrs	Veri yok	Veri yok
Kentaro Suzuki	Chief Marketing Officer	less than a year	Veri yok	Veri yok
Gwen Weld	Chief People Officer	2.6yrs	US$1.87m	0.024% $ 79.2k
Nick Nelson	Chief Business Officer & Senior VP of Business Development	3.4yrs	Veri yok	Veri yok
Subra Sankar	Senior Vice President of Product Development	3.4yrs	US$2.91m	Veri yok

3.4yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: NAUT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sujal Patel	Co-Founder	3.4yrs	US$1.89m	13.67% $ 45.3m
Parag Mallick	Co-Founder	3.4yrs	US$1.02m	16.47% $ 54.6m
Farzad Nazem	Independent Director	3.4yrs	US$189.98k	1.5% $ 5.0m
Matthew McIlwain	Independent Director	3.4yrs	US$202.98k	0.37% $ 1.2m
Ruedi Aebersold	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Leland Hartwell	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Vijay Pande	Independent Director	3.4yrs	US$187.98k	0% $ 0
Matthew Posard	Independent Chairman of the Board	3.4yrs	US$246.98k	0.12% $ 396.0k
Melissa Epperly	Independent Director	3.4yrs	US$202.98k	0% $ 0
Michael Altman	Independent Director	3.4yrs	US$189.98k	0.13% $ 437.9k
Emma Lundberg	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Joshua LaBaer	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NAUT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.4 yıldır).

Nautilus Biotechnology Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Senior Vice President of Operations notifies of intention to sell stock

Nautilus Biotechnology, Inc. Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024

Co-Founder recently bought US$99k worth of stock

High number of new and inexperienced directors

Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating Committee

Recent updates

Price target decreased by 14% to US$3.56

Nautilus Biotechnology, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Senior Vice President of Operations notifies of intention to sell stock

Nautilus Biotechnology, Inc. Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

Nautilus Biotechnology, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Nautilus Biotechnology, Inc., Annual General Meeting, Jun 13, 2024

Nautilus Biotechnology, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Co-Founder recently bought US$99k worth of stock

Consensus revenue estimates decrease by 96%, EPS upgraded

Price target decreased by 8.9% to US$4.25

Price target decreased by 8.3% to US$4.58

Nautilus Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Nautilus Biotechnology, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Price target decreased by 12% to US$4.67

Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth

Nautilus Biotechnology, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Nautilus Biotechnology, Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate

We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth

Nautilus Biotechnology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to US$5.00

High number of new and inexperienced directors

Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating Committee

Nautilus Biotechnology, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Chief People Officer recently bought US$61k worth of stock

Insider recently bought US$163k worth of stock

Co-Founder recently bought US$146k worth of stock

Price target decreased to US$5.67

Nautilus Biotechnology Q2 2022 Earnings Preview

Nautilus Biotechnology, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Co-Founder recently bought US$198k worth of stock

Consensus forecasts updated

Price target decreased to US$8.00

High number of new and inexperienced directors

Nautilus Biotechnology, Inc. Appoints Gwen Weld as Chief People Officer

Nautilus Biotechnology, Inc. to Report Q1, 2022 Results on May 03, 2022

Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Board of Directors

Price target decreased to US$9.33

Nautilus Biotechnology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

The Take On Nautilus Biotechnology

Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point

High number of new and inexperienced directors

CFO & Treasurer recently bought US$69k worth of stock

Independent Director recently bought US$530k worth of stock

Nautilus Biotechnology: Tapping The Potential Of The Human Proteome

Independent Director recently bought US$195k worth of stock

Insider recently bought US$135k worth of stock

Nautilus Biotechnology, Inc. announced that it has received $200 million in funding from a group of investors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş